Clinical Trials Sponsored by Intergroupe Francophone de Cancerologie Thoracique

Total 134 results

Intergroupe Francophone de Cancerologie Thoracique

Recruiting

ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF)

Non Small Cell Lung Cancer | BRAF V600E

France
Intergroupe Francophone de Cancerologie Thoracique

Active, not recruiting

Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (DICIPLE)

Non-Small Cell Lung Cancer Metastatic

France
Intergroupe Francophone de Cancerologie Thoracique

Active, not recruiting

Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL)

Non Small Cell Lung Cancer Metastatic | Brain Metastases | EGFR Activating Mutation | Leptomeningeal Metastasis

France
Intergroupe Francophone de Cancerologie Thoracique

Active, not recruiting

Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY)

Non Small Cell Lung Cancer Metastatic

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements (CLINALK)

Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Mutation

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

French Biological Observatory on Lung Cancer in Never Smokers (BioCAST)

Lung Cancer

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR (LADIE)

Stage IV Lung Cancer

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

A FRENCH SURVEY OF THE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF ELDERLY PEOPLE WITH HISTOLOGICALLY/CYTOLOGICALLY CONFIRMED LUNG CANCER.

Non-small Cell Lung Cancer | ELDERLY PEOPLE

France
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) (ROSIE)

Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR L858R | EGFR DEL19

France
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE)

Non Small Cell Lung Cancer

France
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction (DIAL)

Metastatic NSCLC

France
Intergroupe Francophone de Cancerologie Thoracique

Active, not recruiting

Immunotherapy in Patient With Poor General Condition (SAVIMMUNE)

Non-small Cell Lung Cancer Stage IV

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Chemotherapy for Lung Cancer in HIV-positive Patients (CHIVA)

Non-small Cell Lung Cancer | Hiv-positive

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer. (BUCiL)

Nonsquamous Nonsmall Cell Neoplasm of Lung | Non-small Cell Lung Cancer Metastatic

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer (ACE-Lung)

Non Small Cell Lung Cancer

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Immunotherapy as Second-line in Patient With Small Cell Lung Cancer

Small Cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive Stage

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Adjuvant Pazopanib in Stage I NSCLC

Carcinoma, Non-Small-Cell Lung

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Stage I/II NSCLC Perioperative Chemotherapy

Non-small Cell Lung Cancer Stage I and II | Peri-operative Chemotherapy

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma

Adenocarcinoma, Bronchiolo-Alveolar

France
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) (TAXIO)

Small Cell Lung Cancer Extensive Stage

France
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Non Small Cell Lung Cancer | ALK Gene Mutation

France
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

Non Small Cell Lung Cancer Metastatic

France
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

French National Observatory of Patients With Thymic Epithelial Tumor (RYTHMIC)

Thymic Epithelial Tumor

France
Intergroupe Francophone de Cancerologie Thoracique

Active, not recruiting

Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE)

Non Small Cell Lung Cancer Metastatic

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Her2-positive Lung Cancer Treated With Dedicated Drug (R2D2)

Non Small Cell Lung Cancer Metastatic | HER2 Gene Mutation | Non Small Cell Lung Cancer Stage III

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings

Carcinoma, Non-Small-Cell Lung | KRAS Gene Mutation | ALK Gene Mutation | BRAF Gene Mutation

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Paclitaxel-bevacizumab in Advanced Lung Cancer (Ultimate)

Non-squamous Non-small Cell Lung Cancer

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer (MODEL)

Non Small Cell Lung Cancer (Squamous or Non Squamous)

France
Intergroupe Francophone de Cancerologie Thoracique

Terminated

Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer (IONESCO)

Carcinoma, Non-Small-Cell Lung

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)

Stage III Non-small Cell Lung Cancer

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (MAPS2)

Mesothelioma

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

TAilored Post-Surgical Therapy in Early Stage NSCLC (TASTE)

Carcinoma, Non-Small-Cell Lung

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Bevacizumab in Extensive Small Cell Lung Cancer (CPC)

Small Cell Lung Cancer

France
Intergroupe Francophone de Cancerologie Thoracique

Terminated

NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy

Carcinoma, Non-Small-Cell Lung

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)

NSCLC

France
Intergroupe Francophone de Cancerologie Thoracique
Amgen

Active, not recruiting

RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC (LungKG12Ci)

Nsclc | KRAS P.G12C

France
Intergroupe Francophone de Cancerologie Thoracique
Novartis

Completed

BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation (BLaDE)

Non Small Cell Lung Cancer | BRAF V600 Mutation

France
Intergroupe Francophone de Cancerologie Thoracique
AstraZeneca

Completed

Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

Pneumonic-type Adenocarcinoma (P-ADC) | Lung Adenocarcinoma With Bronchiolo-alveolar Feature

France
Intergroupe Francophone de Cancerologie Thoracique
Pfizer

Completed

Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib (LORLATU)

ALK Gene Rearrangement Positive | Non-small Cell Lung Cancer Metastatic | ROS-1 Gene Rearrangement Positive

France
Intergroupe Francophone de Cancerologie Thoracique
Novartis

Completed

RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) (CapmATU)

Non Small Cell Lung Cancer | MET Alterations | METex14 Mutations

France
Intergroupe Francophone de Cancerologie Thoracique
Sanofi; AstraZeneca

Completed

Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV

Carcinoma, Non-Small-Cell Lung

France
Intergroupe Francophone de Cancerologie Thoracique
Groupe Francais De Pneumo-Cancerologie

Completed

Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

France
Centre Henri Becquerel
Intergroupe Francophone de Cancerologie Thoracique

Unknown

Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC (RTEP7)

Non-small Cell Lung Cancer

France
Intergroupe Francophone de Cancerologie Thoracique
PharmaMar; Groupe Francais De Pneumo-Cancerologie

Completed

RW Effectiveness of Lurbinectedin in Extensive Stage SCLC (LURBICLIN)

Small-cell Lung Cancer

France
Intergroupe Francophone de Cancerologie Thoracique
Roche Pharma AG; GFPC

Completed

Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC (CLINATEZO)

Small Cell Lung Cancer

France
Intergroupe Francophone de Cancerologie Thoracique
Bristol-Myers Squibb

Completed

Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program (CLINIVO)

Non-small Cell Lung Cancer | Nivolumab | Long-term Adverse Effects

France
Intergroupe Francophone de Cancerologie Thoracique
ANRS, Emerging Infectious Diseases

Completed

Immunotherapy by Nivolumab for HIV+ Patients (CHIVA2)

HIV/AIDS | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer Metastatic

France
Intergroupe Francophone de Cancerologie Thoracique
Centre Hospitalier Universitaire de Besancon

Completed

Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Follow-up

Non-Small-Cell Lung Carcinoma

France
UNICANCER
AstraZeneca; Intergroupe Francophone de Cancerologie Thoracique; Fondation ARC

Completed

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (SAFIR02_Lung)

Non-small Cell Lung Cancer Metastatic

France
Intergroupe Francophone de Cancerologie Thoracique
Federation Francophone de Cancerologie Digestive; GERCOR - Multidisciplinary...

Active, not recruiting

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC)

Neuroendocrine Carcinoma

France

Clinical Trials Sponsored by Intergroupe Francophone de Cancerologie Thoracique

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations